Alexion Pharmaceuticals
| Use attributes for filter ! | |
| Web site | www.alexion.com |
|---|---|
| Headquarters | New Haven |
| Connecticut | |
| United States | |
| Ceo | Ludwig N. Hantson |
| Revenue | 3. 551 billion USD (2017) |
| Number of employees | 2,525 (2017) |
| Subsidiaries | Syntimmune, Inc. |
| Alexion International Sarl | |
| Address | İstanbul İçerenköy Mahallesi Umut Sk. 10-12 Kat:17, 34752 Ataşehir |
| Phone | (0212) 355 54 00 |
| Date of Reg. | |
| Date of Upd. | |
| ID | 672611 |
About Alexion Pharmaceuticals
Alexion Pharmaceuticals Inc. is an American pharmaceutical company best known for its development of Soliris, a drug used to treat the rare disorders atypical hemolytic uremic syndrome and paroxysmal nocturnal hemoglobinuria. The company is also involved in immune system research related to autoimmune diseases.
Where is the Alexion Pharmaceuticals
Click on the photo of Alexion Pharmaceuticals to view it on Google Maps.
